IRIS UniCatt

Bria, Emilio
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 2.719
EU - Europa 2.188
AS - Asia 1.308
SA - Sud America 208
AF - Africa 49
Continente sconosciuto - Info sul continente non disponibili 6
OC - Oceania 2
Totale 6.480
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 2.684
SE - Svezia 601
SG - Singapore 577
IT - Italia 519
CN - Cina 247
IN - India 220
DE - Germania 203
BR - Brasile 191
IE - Irlanda 180
FR - Francia 170
PL - Polonia 142
ID - Indonesia 119
RU - Federazione Russa 70
GB - Regno Unito 66
FI - Finlandia 49
HK - Hong Kong 42
AT - Austria 31
CI - Costa d'Avorio 30
NL - Olanda 30
IR - Iran 22
BE - Belgio 21
CA - Canada 20
CZ - Repubblica Ceca 20
UA - Ucraina 17
ES - Italia 14
CH - Svizzera 12
TR - Turchia 11
VN - Vietnam 10
JP - Giappone 8
LT - Lituania 8
PK - Pakistan 7
LV - Lettonia 6
MX - Messico 6
AR - Argentina 5
CO - Colombia 5
HU - Ungheria 5
IL - Israele 5
KR - Corea 5
BD - Bangladesh 4
EG - Egitto 4
EU - Europa 4
IQ - Iraq 4
LU - Lussemburgo 4
SI - Slovenia 4
TW - Taiwan 4
AE - Emirati Arabi Uniti 3
AZ - Azerbaigian 3
CR - Costa Rica 3
DZ - Algeria 3
KZ - Kazakistan 3
MA - Marocco 3
NO - Norvegia 3
PY - Paraguay 3
SA - Arabia Saudita 3
TN - Tunisia 3
A2 - ???statistics.table.value.countryCode.A2??? 2
AU - Australia 2
BG - Bulgaria 2
CY - Cipro 2
DO - Repubblica Dominicana 2
EC - Ecuador 2
GG - Guernsey 2
HN - Honduras 2
KE - Kenya 2
PA - Panama 2
PH - Filippine 2
RO - Romania 2
UZ - Uzbekistan 2
ZA - Sudafrica 2
AL - Albania 1
AM - Armenia 1
CL - Cile 1
GE - Georgia 1
GR - Grecia 1
HR - Croazia 1
IS - Islanda 1
KG - Kirghizistan 1
MD - Moldavia 1
NG - Nigeria 1
OM - Oman 1
PT - Portogallo 1
QA - Qatar 1
RS - Serbia 1
SC - Seychelles 1
VE - Venezuela 1
Totale 6.480
Salva come PNG Salva come JPEG
Città #
Chandler 550
Singapore 355
Ashburn 279
Dublin 173
Fairfield 161
Hyderabad 154
Warsaw 142
Rome 129
Jakarta 117
Wilmington 98
Princeton 91
New York 89
The Dalles 87
San Mateo 84
Houston 72
Milan 71
Seattle 67
Boston 56
Moscow 55
Woodbridge 55
Cambridge 47
Ann Arbor 43
Cattolica 43
Helsinki 42
Marseille 40
Beijing 39
Hong Kong 39
Frankfurt am Main 38
Boardman 37
Chicago 33
Abidjan 30
Bremen 29
Los Angeles 28
Düsseldorf 26
London 25
Redwood City 25
Dearborn 23
Nanjing 23
Nuremberg 22
Brussels 20
Augusta 16
North Bergen 16
Paris 16
Andover 15
Brno 14
Jacksonville 14
Redmond 14
Vienna 14
Kish 13
Norwalk 13
Falkenstein 12
Munich 12
Lauterbourg 11
Nanchang 11
Madrid 10
San Diego 10
Busto Arsizio 9
Dong Ket 9
Guangzhou 9
Hangzhou 9
São Paulo 9
Bengaluru 8
Toronto 8
Council Bluffs 7
Florence 7
Lappeenranta 7
Piacenza 7
Portsmouth 7
Pune 7
Tokyo 7
Washington 7
Goiânia 6
Izmir 6
Leawood 6
Padova 6
Rio de Janeiro 6
Santa Clara 6
Shanghai 6
Zurich 6
Amsterdam 5
Bari 5
Campinas 5
Curitiba 5
Des Moines 5
Hebei 5
Hefei 5
Montesilvano Marina 5
Mountain View 5
Newark 5
Prague 5
Seoul 5
Bern 4
Caserta 4
Dallas 4
Duncan 4
Modugno 4
Montepulciano 4
Ottawa 4
Riga 4
Sacramento 4
Totale 4.009
Salva come PNG Salva come JPEG
Nome #
Pembrolizumab as first-line treatment for metastatic uveal melanoma 279
C-myc expression is a possible keystone in the colorectal cancer resistance to egfr inhibitors 214
Gene Expression Profiling of Lung Atypical Carcinoids and Large Cell Neuroendocrine Carcinomas Identifies Three Transcriptomic Subtypes with Specific Genomic Alterations 206
Diagnosis and treatment of bone metastases in breast cancer: Radiotherapy, local approach and systemic therapy in a guide for clinicians 169
c-MYC Expression Is a Possible Keystone in the Colorectal Cancer Resistance to EGFR Inhibitors. 135
Development of a digital research assistant for the management of patients’ enrollment in oncology clinical trials within a research hospital 124
191P Radiotherapy (RT) in oligoprogressive metastatic breast cancer (mBC): A retrospective analysis 108
Liver metastasectomy for metastatic breast cancer patients: A single institution retrospective analysis 105
Intratumoral injection of TLR9 agonist promotes an immunopermissive microenvironment transition and causes cooperative antitumor activity in combination with anti-PD1 in pancreatic cancer 96
The prognostic relevance of HER2-positivity gain in metastatic breast cancer in the ChangeHER trial 91
[Use of the Lean methodology in the management of cancer patients in a University Hospital, Italy: First results] 90
Blood serum amyloid A as potential biomarker of pembrolizumab efficacy for patients affected by advanced non-small cell lung cancer overexpressing PD-L1: results of the exploratory “FoRECATT” study 90
Radiotherapy benefit in oligoprogressive breast cancer: A retrospective analysis 89
Impact of BMI on HER2+ metastatic breast cancer patients treated with pertuzumab and/or trastuzumab emtansine. Real-world evidence 89
[Use of the Lean methodology in the management of cancer patients in a University Hospital, Italy: First results] 87
Targeted next-generation sequencing identifies genomic abnormalities potentially driving the prognosis of early-stage invasive lobular breast carcinoma patients stratified according to a validated clinico-pathological model 83
Body composition changes in gastric cancer patients during preoperative flot therapy: Preliminary results of an italian cohort study 82
Liver metastasectomy for metastatic breast cancer patients: A single institution retrospective analysis 81
Skeletal Muscle Loss during Multikinase Inhibitors Therapy: Molecular Pathways, Clinical Implications, and Nutritional Challenges. 78
The impact of multidisciplinary team management on outcome of hepatic resection in liver-limited colorectal metastases 77
Muscle mass, assessed at diagnosis by L3-CT scan as a prognostic marker of clinical outcomes in patients with gastric cancer: A systematic review and meta-analysis. 76
Lung cancer multi-omics digital human avatars for integrating precision medicine into clinical practice: the LANTERN study 75
The facts about food after cancer diagnosis: A systematic review of prospective cohort studies 75
Palbociclib plus fulvestrant or everolimus plus exemestane for pretreated advanced breast cancer with lobular histotype in er+/her2− patients: A propensity score-matched analysis of a multicenter retrospective patient series 74
Masaoka-koga and tnm staging system in thymic epithelial tumors: Prognostic comparison and the role of the number of involved structures 72
Immunological backbone of uveal melanoma: Is there a rationale for immunotherapy? 71
PTEN Loss as a Predictor of Tumor Heterogeneity and Poor Prognosis in Patients With EGFR-mutant Advanced Non–small-cell Lung Cancer Receiving Tyrosine Kinase Inhibitors 71
Dabrafenib and Trametinib in BRAF Mutant Metastatic Conjunctival Melanoma 70
Effects of nutritional interventions on nutritional status in patients with gastric cancer: A systematic review and meta-analysis of randomized controlled trials 67
Evidence-based tailored nutrition educational intervention improves adherence to dietary guidelines, anthropometric measures and serum metabolic biomarkers in early-stage breast cancer patients: A prospective interventional study 67
Bevacizumab as maintenance therapy in patients with metastatic colorectal cancer: A meta-analysis of individual patients’ data from 3 phase III studies 66
Development of a digital research assistant for the management of patients’ enrollment in oncology clinical trials within a research hospital 66
Clinical, pathological and prognostic features of rare braf mutations in metastatic colorectal cancer (Mcrc): A bi-institutional retrospective analysis (rebus study) 66
The likelihood of being helped or harmed as a patient-centred tool to assess cyclin dependent kinase 4/6 inhibitors clinical impact and safety in metastatic breast cancer: a systematic review and sensitivity-analysis 65
Prognostic Model for Resected Squamous Cell Lung Cancer: External Multicenter Validation and Propensity Score Analysis exploring the Impact of Adjuvant and Neoadjuvant Treatment 65
Distinct HR expression patterns significantly affect the clinical behavior of metastatic HER2+ breast cancer and degree of benefit from novel anti-HER2 agents in the real world setting 64
Impact on survival of primary tumor resection in patients with metastatic breast cancer: preliminary results of a retrospective analisys 64
Prognostic Factors in Patients with Breast Cancer Liver Metastases Undergoing Liver Resection: Systematic Review and Meta-Analysis 64
Exploring the molecular and biological background of lung neuroendocrine tumours 63
Loss of HER2 and decreased T-DM1 efficacy in HER2 positive advanced breast cancer treated with dual HER2 blockade: the SePHER Study 63
Oncogene-addicted non-small-cell lung cancer: Treatment opportunities and future perspectives 62
Conjunctival melanoma: Genetic and epigenetic insights of a distinct type of melanoma 61
Prognostic value of skeletal muscle mass during tyrosine kinase inhibitor (TKI) therapy in cancer patients: a systematic review and meta-analysis 61
Going towards a precise definition of the therapeutic management of de-novo metastatic castration sensitive prostate cancer patients: How prognostic classification impact treatment decisions 60
Poor efficacy of palbociclib in second-line treatment of metastatic lobular breast cancer in a case series: Use before or never more? 58
Prognostic factors and long-term survival in locally advanced nsclc with pathological complete response after surgical resection following neoadjuvant therapy 57
Neoadjuvant treatment: A window of opportunity for nutritional prehabilitation in patients with pancreatic ductal adenocarcinoma 57
Advances towards the design and development of personalized non-small-cell lung cancer drug therapy 56
Poor efficacy of palbociclib in second-line treatment of metastatic lobular breast cancer in a case series: Use before or never more? 56
Collagenous colitis and atezolizumab therapy: an atypical case. 56
PD-L1 for selecting non-small-cell lung cancer patients for first-line immuno-chemotherapy combination: A systematic review and meta-analysis 55
A multicenter REtrospective observational study of first-line treatment with PERtuzumab, trastuzumab and taxanes for advanced HER2 positive breast cancer patients. RePer Study 54
Percutaneous radiofrequency ablation using internally cooled wet electrodes for the treatment of patients with lung tumors 54
Symptomatic androgen deficiency and sexual dysfunctions in male patients receiving alectinib for ALK-positive advanced nonsmall cell lung cancer 53
Prognostic impact of early nutritional support in patients affected by locally advanced and metastatic pancreatic ductal adenocarcinoma undergoing chemotherapy 53
Nutritional Support in Lung Cancer Patients: The State of the Art 53
PD-L1 Expression in de Novo Metastatic Castration-sensitive Prostate Cancer 52
Survival analysis in single N2 station lung adenocarcinoma: The prognostic role of involved lymph nodes and adjuvant therapy 52
External validation of the N descriptor in the proposed tumour-node-metastasis subclassification for lung cancer: The crucial role of histological type, number of resected nodes and adjuvant therapy 52
Clinical Stage III NSCLC Patients Treated with Neoadjuvant Therapy and Surgery: The Prognostic Role of Nodal Characteristics 45
Bronchoscopically-visible massive central airway cancer cavitation is associated with metastatic disease, lack of actionable mutations and poor prognosis: a case series 45
Risk Stratification Model for Resected Squamous-Cell Lung Cancer Patients According to Clinical and Pathological Factors 45
Impact of Comprehensive Genome Profiling on the Management of Advanced Non–Small Cell Lung Cancer: Preliminary Results From the Lung Cancer Cohort of the FPG500 Program 43
Intrathoracic Lymph Node Microcalcifications are Associated With a High Prevalence of Malignancy and Anaplastic Lymphoma Kinase Rearrangement: The "Calce" Study 43
Advances towards the design and development of personalized non-small-cell lung cancer drug therapy 43
Large Cell Neuro-Endocrine Carcinoma of the Lung: Current Treatment Options and Potential Future Opportunities 42
Atezolizumab Plus Carboplatin and Etoposide in Patients with Untreated Extensive-Stage Small-Cell Lung Cancer: Interim Results of the MAURIS Phase IIIb Trial 41
Impact on survival of primary tumor resection in patients with metastatic breast cancer: preliminary results of a retrospective analysis 40
Harnessing the epigenome to boost immunotherapy response in non-small cell lung cancer patients 39
PTEN in colorectal cancer: Shedding light on its role as predictor and target 39
Leptin-mediated meta-inflammation may provide survival benefit in patients receiving maintenance immunotherapy for extensive-stage small cell lung cancer (ES-SCLC) 39
Salvage Surgery After First-Line Alectinib for Locally-Advanced/Metastatic ALK-Rearranged NSCLC: Pathological Response and Perioperative Results 37
Clinical implication of changes in body composition and weight in patients with early-stage and metastatic breast cancer 37
Predictive and prognostic effect of computed tomography-derived body composition analysis during neoadjuvant chemotherapy for operable and locally advanced breast cancer 36
ALK gene copy number gains in non-small-cell lung cancer: Prognostic impact and clinico-pathological correlations 36
Differential activity of nivolumab, pembrolizumab and MPDL3280A according to the tumor expression of programmed death-ligand-1 (PD-L1): Sensitivity analysis of trials in melanoma, lung and genitourinary cancers 36
Role of Peripheral Blood Markers for Detecting Response and Predicting Prognosis in Patients with Non-small-cell Lung Cancer Undergoing Neoadjuvant Therapy and Surgery 35
Circulating immune profile can predict survival of metastatic uveal melanoma patients: results of an exploratory study 35
Clinico-pathological nomogram for predicting BRAF mutational status of metastatic colorectal cancer 35
Characterization of Myeloid-derived Suppressor Cells in a Patient With Lung Adenocarcinoma Undergoing Durvalumab Treatment: A Case Report 35
Is Surgery Worthwhile in Locally-advanced NSCLC Patients with Persistent N2-disease After Neoadjuvant Therapy? 35
Correction: Lung cancer multi-omics digital human avatars for integrating precision medicine into clinical practice: the LANTERN study 35
Comprehensive molecular portrait using next generation sequencing of resected intestinal-type gastric cancer patients dichotomized according to prognosis 33
Lymph-node ratio predicts survival among the different stages of non-small-cell lung cancer: A multicentre analysis 32
Development of a nomogram for predicting pathological complete response in luminal breast cancer patients following neoadjuvant chemotherapy 31
Talniflumate abrogates mucin immune suppressive barrier improving efficacy of gemcitabine and nab-paclitaxel treatment in pancreatic cancer 30
Molecular heterogeneity assessment by next-generation sequencing and response to gefitinib of EGFR mutant advanced lung adenocarcinoma 30
Exploratory analysis of the effect of a dexamethasone-sparing regimen for prophylaxis of cisplatin-induced emesis on food intake (LUNG-NEPA study) 29
Muscle derangement and alteration of the nutritional machinery in NSCLC 27
Prognostic model for advanced breast carcinoma with luminal subtype and impact of hormonal maintenance: Implications for post-progression and conditional survival 26
Crizotinib in MET-Deregulated or ROS1-Rearranged Pretreated Non-Small Cell Lung Cancer (METROS): A Phase II, Prospective, Multicenter, Two-Arms Trial 26
Lung neuroendocrine tumours: deep sequencing of the four World Health Organization histotypes reveals chromatin-remodelling genes as major players and a prognostic role for TERT, RB1, MEN1 and KMT2D 26
Cryoablation in Locoregional Management of Complex Unresectable Chest Neoplasms 25
Tracking MET de-addiction in lung cancer: A road towards the oncogenic target 25
Subpopulation Treatment Effect Pattern Plot (STEPP) analysis of Ki67 assay according to histology: Prognostic relevance for resected early stage 'pure' and 'mixed' lobular breast cancer 25
Oncological Frontiers in the Treatment of Malignant Pleural Mesothelioma 24
Interfering with CCL5/CCR5 at the Tumor-Stroma Interface 24
Hyperprogressive Disease in Patients with Advanced Non-Small Cell Lung Cancer Treated with PD-1/PD-L1 Inhibitors or with Single-Agent Chemotherapy 24
Revising PTEN in the era of immunotherapy: New perspectives for an old story 23
Maintenance with lanreotide in small-cell lung cancer expressing somatostatine receptors: A multicenter, randomized, phase 3 trial 23
Totale 6.178
Salva come PNG Salva come JPEG
Categoria #
all - tutte 40.632
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 40.632
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020165 0 0 0 0 0 0 0 0 0 0 133 32
2020/2021462 24 27 50 39 85 17 40 3 45 44 62 26
2021/2022914 107 39 18 101 37 38 23 139 48 27 157 180
2022/20231.699 266 207 134 241 75 201 99 125 176 57 67 51
2023/20241.055 36 250 39 49 41 114 108 53 17 56 128 164
2024/20251.932 88 42 204 99 177 80 152 117 460 453 60 0
Totale 6.694